Patent Settlements in the Pharmaceutical Industry: What Can We Learn from Economic Analysis?

@article{Frank2015PatentSI,
  title={Patent Settlements in the Pharmaceutical Industry: What Can We Learn from Economic Analysis?},
  author={Jonas Manuel Frank and Wolfgang Kerber},
  journal={Sustainable Technology eJournal},
  year={2015}
}
Patent settlements between originator and generic firms in the pharmaceutical industry have been challenged by antitrust and competition authorities in the U.S. and the EU. Particularly settlements with large "reverse payments" to generic firms raise the concern of collusive behaviour for protecting weak patents and delaying price competition through generic entry and therefore harming consumers. However, it is still heavily disputed under what conditions such patent settlements are… Expand
5 Citations
Optimal Incentives for Patent Challenges in the Pharmaceutical Industry
Since the patent system relies on private litigation for challenging weak patents, and patent settlements might influence the incentives for challenging patents, the question arises whether theExpand
Reverse Payment Patent Settlements in the Pharmaceutical Sector Under EU and US Competition Laws: A Comparative Analysis
Within the tool-box developed by originator companies in order to prepare and respond to generic entry, a prominent position must be recognized to a category of patent strategies particularlyExpand
Patent Settlements in Europe and the Lundbeck Case: A Competition Law and Economics Perspective
The paper studies the Lundbeck patent settlement antitrust case of the European Commission from an economic perspective. The Commission concludes that the agreements in Lundbeck involving reverseExpand
Anticompetitive Patent Settlements – Where Are We Ten Years After the European Commission’s Pharmaceutical Inquiry?
In 2009, the European Commission published a final report on its market inquiry into the pharmaceutical sector. The report revealed the authority’s concerns regarding market practices ofExpand
Optimal Incentives for Patent Challenges in the Pharmaceutical Industry
In this paper, we show that a provision in antitrust law to allow patent settlements with a later market entry of generics than the date that is expected under patent litigation can increase consumerExpand

References

SHOWING 1-10 OF 89 REFERENCES
Patent Settlements in the Pharmaceutical Industry: An Antitrust Perspective
Patent settlements between originator and generic firms in the pharmaceutical industry are a controversial topic, both in EU competition policy and U.S. antitrust law. The main concern is that patentExpand
Optimal Incentives for Patent Challenges in the Pharmaceutical Industry
Since the patent system relies on private litigation for challenging weak patents, and patent settlements might influence the incentives for challenging patents, the question arises whether theExpand
Patent settlements and competition law: where is the European Commission going?
One of the clearer messages from the EU Pharmaceutical Sector Inquiry was that the European Commission believes some patent settlement agreements—in particular those involving payments from theExpand
An economic assessment of patent settlements in the pharmaceutical industry.
TLDR
The authors conclude that while continued scrutiny of such settlements is important, broad brush treatments are inappropriate and only a more individualized evaluation can correctly determine the competitive effects of a particular settlement agreement. Expand
Why the 'Scope of the Patent' Test Cannot Solve the Drug Patent Settlement Problem
One of the most difficult legal issues today involves settlements by which brand-name drug companies pay generic firms to delay entering the market. Such conduct requires courts to consider not onlyExpand
Why Brand Pharmaceutical Companies Choose to Pay Generics in Settling Patent Disputes: A Systematic Evaluation of Asymmetric Risks in Litigation
In this paper we developed a probabilistic model to examine the financial risks for a brand and a generic pharmaceutical manufacturer in Paragraph IV patent litigation arising out of the Hatch-WaxmanExpand
Solving the Patent Settlement Puzzle
Courts and commentators are sharply divided about how to assess “reverse payment” patent settlements under antitrust law. The essential problem is that a PTO-issued patent provides only aExpand
Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
  • T. Leary
  • Medicine
  • Journal of health law
  • 2001
TLDR
The settlement of patent disputes in the pharmaceutical industry, and the possible antitrust issues arising therefrom, are of notable concern to the Federal Trade Commission, and Commissioner Leary re-examines earlier positions under the light of the Commission's further experience with these matters, and provides the industry with some additional objective standards under which it may legally operate. Expand
Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
The settlement of patent disputes in the pharmaceutical industry, and the possible antitrust issues arising therefrom, are of notable concern to the Federal Trade Commission. In this Comment, basedExpand
Actavis and Multiple ANDA Entrants: Beyond the Temporary Duopoly
This paper examines the economics of litigation and settlement of patent disputes arising from Paragraph IV ANDA filings under the Drug Price Competition and Patent Term Restoration ActExpand
...
1
2
3
4
5
...